Log in

NASDAQ:ADRO - Aduro BioTech Stock Price, Forecast & News

$2.51
+0.09 (+3.72 %)
(As of 04/3/2020 04:59 AM ET)
Today's Range
$2.39
Now: $2.51
$2.54
50-Day Range
$2.01
MA: $2.96
$3.87
52-Week Range
$0.90
Now: $2.51
$4.59
Volume242,453 shs
Average Volume1.24 million shs
Market Capitalization$202.71 million
P/E RatioN/A
Dividend YieldN/A
Beta0.33
Aduro BioTech, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies to harness the body's natural immune system for the treatment of patients with challenging diseases. The company is developing ADU-S100, which is in Phase I dose escalation and dose expansion clinical trial and Phase Ib dose escalation and dose expansion clinical trial in combination with spartalizumab to treat patients with advanced, metastatic treatment-refractory solid tumors; Phase I clinical trial in combination with ipilimumab for the treatment of relapsed and refractory melanoma; and Phase Ib/II clinical trial in combination with an approved anti-PD-1 antibody in patients with squamous cell carcinoma of the head and neck. It is also developing product candidates to prevent or control immune responses through the stimulator of interferon genes pathway. In addition, the company is developing BION-1301, a fully blocking humanized monoclonal anti-APRIL antibody that is in Phase I clinical trial for IgA nephropathy and multiple myeloma; and CD27, a co-stimulatory receptor, which is in preclinical studies expressed on different immune cells, such as T-lymphocytes and NK cells. It has collaboration agreements with Novartis Pharmaceuticals Corporation, Eli Lilly and Company, and Merck Sharp and Dohme B.V.; license agreements with Karagen Pharmaceuticals, Inc., UC Berkeley, and Memorial Sloan Kettering Cancer Center. The company was formerly known as Oncologic, Inc. and changed its name to Aduro BioTech, Inc. in June 2008. Aduro BioTech, Inc. was founded in 2000 and is based in Berkeley, California.
Read More
Aduro BioTech logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ADRO
CUSIPN/A
Phone510-848-4400

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$17.26 million
Book Value$0.81 per share

Profitability

Net Income$-82,370,000.00
Net Margins-477.30%

Miscellaneous

Employees152
Market Cap$202.71 million
Next Earnings Date5/5/2020 (Estimated)
OptionableOptionable

Receive ADRO News and Ratings via Email

Sign-up to receive the latest news and ratings for ADRO and its competitors with MarketBeat's FREE daily newsletter.


Aduro BioTech (NASDAQ:ADRO) Frequently Asked Questions

How has Aduro BioTech's stock been impacted by COVID-19 (Coronavirus)?

Aduro BioTech's stock was trading at $2.36 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ADRO stock has increased by 6.4% and is now trading at $2.51. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Aduro BioTech?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aduro BioTech in the last year. There are currently 4 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Aduro BioTech.

When is Aduro BioTech's next earnings date?

Aduro BioTech is scheduled to release its next quarterly earnings announcement on Tuesday, May 5th 2020. View our earnings forecast for Aduro BioTech.

How were Aduro BioTech's earnings last quarter?

Aduro BioTech Inc (NASDAQ:ADRO) issued its quarterly earnings results on Monday, March, 9th. The biotechnology company reported ($0.24) EPS for the quarter, missing analysts' consensus estimates of ($0.21) by $0.03. The biotechnology company had revenue of $3.63 million for the quarter, compared to analysts' expectations of $4.95 million. Aduro BioTech had a negative return on equity of 90.50% and a negative net margin of 477.30%. View Aduro BioTech's earnings history.

What price target have analysts set for ADRO?

6 brokers have issued 1 year price objectives for Aduro BioTech's shares. Their forecasts range from $4.00 to $7.00. On average, they anticipate Aduro BioTech's stock price to reach $5.50 in the next twelve months. This suggests a possible upside of 119.1% from the stock's current price. View analysts' price targets for Aduro BioTech.

Has Aduro BioTech been receiving favorable news coverage?

News articles about ADRO stock have trended very negative on Friday, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Aduro BioTech earned a media sentiment score of -3.3 on InfoTrie's scale. They also assigned media stories about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near future. View the latest news aboutAduro BioTech.

Are investors shorting Aduro BioTech?

Aduro BioTech saw a increase in short interest in the month of February. As of February 28th, there was short interest totaling 3,450,000 shares, an increase of 8.5% from the February 13th total of 3,180,000 shares. Based on an average daily trading volume, of 1,300,000 shares, the days-to-cover ratio is presently 2.7 days. Approximately 6.8% of the shares of the stock are short sold. View Aduro BioTech's Current Options Chain.

Who are some of Aduro BioTech's key competitors?

What other stocks do shareholders of Aduro BioTech own?

Who are Aduro BioTech's key executives?

Aduro BioTech's management team includes the following people:
  • Mr. Stephen T. Isaacs, Chairman, CEO & Pres (Age 70)
  • Dr. Andrea van Elsas, Chief Scientific Officer (Age 52)
  • Mr. Blaine E. Templeman, Chief Admin. Officer & Chief Legal Officer (Age 53)
  • Ms. Jennifer Lew, Chief Financial Officer (Age 46)
  • Ms. Alexandra Santos, Exec. Director of Corp. Affairs & Investor Relations

When did Aduro BioTech IPO?

(ADRO) raised $119 million in an initial public offering (IPO) on Wednesday, April 15th 2015. The company issued 7,000,000 shares at $17.00 per share. BofA Merrill Lynch and Leerink Partners acted as the underwriters for the IPO and William Blair and Canaccord Genuity were co-managers.

What is Aduro BioTech's stock symbol?

Aduro BioTech trades on the NASDAQ under the ticker symbol "ADRO."

How do I buy shares of Aduro BioTech?

Shares of ADRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Aduro BioTech's stock price today?

One share of ADRO stock can currently be purchased for approximately $2.51.

How big of a company is Aduro BioTech?

Aduro BioTech has a market capitalization of $202.71 million and generates $17.26 million in revenue each year. The biotechnology company earns $-82,370,000.00 in net income (profit) each year or ($1.03) on an earnings per share basis. Aduro BioTech employs 152 workers across the globe. View additional information about Aduro BioTech.

What is Aduro BioTech's official website?

The official website for Aduro BioTech is http://www.aduro.com/.

How can I contact Aduro BioTech?

Aduro BioTech's mailing address is 740 HEINZ AVENUE, BERKELEY CA, 94710. The biotechnology company can be reached via phone at 510-848-4400 or via email at [email protected]


MarketBeat Community Rating for Aduro BioTech (NASDAQ ADRO)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  450 (Thanks for Voting!)
Underperform Votes:  268 (Thanks for Voting!)
Total Votes:  718
MarketBeat's community ratings are surveys of what our community members think about Aduro BioTech and other stocks. Vote "Outperform" if you believe ADRO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ADRO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/3/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel